Journal article
CGRP in Animal Models of Migraine
Handbook of experimental pharmacology, Vol.255, pp.85-107
2019
DOI: 10.1007/164_2018_187
PMCID: PMC7008000
PMID: 30689086
Abstract
With the approval of calcitonin gene-related peptide (CGRP) and CGRP receptor monoclonal antibodies by the Federal Drug Administration, a new era in the treatment of migraine patients is beginning. However, there are still many unknowns in terms of CGRP mechanisms of action that need to be elucidated to allow new advances in migraine therapies. CGRP has been studied both clinically and preclinically since its discovery. Here we review some of the preclinical data regarding CGRP in animal models of migraine.
Details
- Title: Subtitle
- CGRP in Animal Models of Migraine
- Creators
- Anne-Sophie Wattiez - Center for the Prevention and Treatment of Visual Loss, Iowa VA Health Care System, Iowa City, IA, USAMengya Wang - Department of Pharmacology, University of Iowa, Iowa City, IA, USAAndrew F Russo - Department of Pharmacology, University of Iowa, Iowa City, IA, USA. andrew-russo@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Handbook of experimental pharmacology, Vol.255, pp.85-107
- DOI
- 10.1007/164_2018_187
- PMID
- 30689086
- PMCID
- PMC7008000
- NLM abbreviation
- Handb Exp Pharmacol
- eISBN
- 9783030214548; 3030214540
- ISSN
- 0171-2004
- eISSN
- 1865-0325
- Publisher
- Germany
- Grant note
- I01 RX002101 / RRD VA R01 NS075599 / NINDS NIH HHS
- Language
- English
- Date published
- 2019
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984070793802771
Metrics
44 Record Views